Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 15/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18560568 | 1.00 | SYK (1.00) | SYKKCNH2CYP2D6 | |
| SCHEMBL15091163 | 0.97 | SYK (0.94) | SYKKCNH2CYP2D6 | |
| SCHEMBL15091158 | 0.89 | SYK (0.81) | SYKKCNH2CYP2D6 | |
| SCHEMBL15091146 | 0.89 | SYK (0.81) | SYKKCNH2CYP2D6 | |
| SCHEMBL15090996 | 0.88 | SYK (1.00) | SYKKCNH2CYP2D6 | |
| SCHEMBL15091041 | 0.87 | SYK (1.00) | SYKKCNH2CYP2D6 | |
| SCHEMBL15091087 | 0.87 | SYK (1.00) | SYKKCNH2CYP2D6 | |
| SCHEMBL15096263 | 0.87 | SYK (1.00) | SYKKCNH2CYP2D6 | |
| SCHEMBL15091222 | 0.87 | SYK (0.76) | SYKKCNH2CYP2D6 | |
| SCHEMBL15091225 | 0.87 | SYK (0.76) | SYKKCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802567-B1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | claimed |
| US-8901124-B2 | Pyridazine amide compounds useful as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-12-02 | — | — | US | claimed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | claimed |
| EP-2802567-B1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| EP-2802567-B1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-8901124-B2 | Pyridazine amide compounds useful as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901124-B2 | Pyridazine amide compounds useful as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901124-B2 | Pyridazine amide compounds useful as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2013104573-A1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | SYK, BTK, IRAK2 | SYK 1/4885KCNH2 2287/4885CYP2D6 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.